[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"adaptive-radiotherapy\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:adaptive-radiotherapy":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,44,75,103,127,156,182,203,230,255,281],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100543375","ultrahypofractionated-adaptive-radiation-therapy-of-prostate-cancer-100543375",false,"NCT06355050","Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer","Ultrahypofractionated, Adaptive Radiation Therapy of Prostate Cancer - Ultra-HART","ultraHART","Inclusion Criteria:\n\n* no androgen deprivation therapy within the last 2 months prior to RT\n* good performance status (Eastern Cooperative Oncology Group, ECOG, 0\u002F1)\n* no secondary malignancy","MALE","18 Years","120 Years",{"count":21,"type":22},150,"ESTIMATED","OBSERVATIONAL","In this prospective, multi-center cohort study, the tolerability and quality of life during ultrahypofractionated radiotherapy (RT) of early stage prostate cancer is surveyed at several institutions in Germany. Radiotherapy is delivered by an online-adaptive RT device (Varian Ethos), which is able to correct daily variations in anatomy and to adjust the irradiation plan accordingly. A digital patient questionnaire is used to asses quality of life longitudinally. Quality of life (QoL) and toxicity profiles will be correlated with planning parameters and compared to retrospective cohorts of patients who underwent normofractionated RT or moderately hypofractionated RT, respectively.",[26,27,28],"Prostate Cancer","Adaptive Radiotherapy","Quality of Life",[27,28,30],"Ultra-hypofractionation","RECRUITING","2026-06-09",{"date":34,"type":35},"2026-06-11","ACTUAL",{"date":37,"type":35},"2026-04-01",{"date":39,"type":22},"2032-09-30",{"name":41,"class":42},"Jena University Hospital","OTHER",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":52,"enrollmentInfo":53,"targetDuration":4,"studyType":55,"phases":56,"briefSummary":58,"conditions":59,"keywords":62,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":43},"100603610","phase-2-the-efficacy-and-safety-of-the-combination-of-pd-1-with-chemotherapy-and-adaptive-radiotherapy-strategy-in-the-treatment-of-stage-iii-non-small-cell-lung-cancer-patients-100603610","NCT07138755","The Efficacy and Safety of the Combination of PD-1 With Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","The Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients","Inclusion Criteria:\n\n1. The subjects are willing and able to comply with the scheduled visits, treatment plans, laboratory tests, and other requirements of the study\n2. Age range of 18-75 years old upon enrollment, both male and female are eligible\n3. Stage III NSCLC confirmed by histology or cytology (according to the International Union Against Cancer and the Joint American Committee on Cancer 8th edition TNM staging of lung cancer)\n4. It was clarified that surgical resection is not possible After MDT discussion,\n5. The main driver genes have no sensitive mutations (including EGFR, ALK, ROS1, MET, HER2, etc.)\n6. No previous systematic anti-tumor treatment or chest radiotherapy for NSCLC\n7. According to RECIST v1.1, there is at least one measurable lesion, and according to RECIST v1.1, this lesion is suitable for repeated and accurate measurements\n8. There is sufficient organ function reserve to meet the needs of clinical research\n\nExclusion Criteria:\n\n1. There are any small cell carcinoma components present in the histopathology, as well as special types such as salivary gland type and SMARCA4 deficiency\n2. Except for NSCLC, the subjects had other malignant tumors within the 5 years prior to enrollment. Subjects with other tumors that have been cured by local treatment, such as basal or cutaneous squamous cell carcinoma, superficial bladder cancer, cervical or breast cancer in situ, are not excluded\n3. Previously received local treatments for tumor lesions such as thoracic radiotherapy and radiofrequency ablation\n4. Received non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, tumor necrosis factor, etc., excluding IL-11 used to treat thrombocytopenia) within 2 weeks before the first administration; Received Chinese herbal medicine or traditional Chinese patent medicines and simple preparations with anti-tumor indications within 1 week before the first administration\n5. Suffering from active autoimmune diseases that require systematic treatment within the past two years\n6. History of immunodeficiency; Individuals who test positive for HIV antibodies; Currently in long-term use of systemic corticosteroids or other immunosuppressants\n7. Subjects who are known to have active pulmonary tuberculosis (TB) and suspected of having TB need to undergo clinical examination to exclude them; Known active syphilis infection\n8. Known history of allogeneic organ transplantation and allogeneic hematopoietic stem cell transplantation\n9. Previous or current non infectious pneumonia\u002Finterstitial lung disease requiring systemic corticosteroid therapy\n10. Serious infection occurred within 4 weeks prior to the first administration, including but not limited to comorbidities requiring hospitalization, sepsis, or severe pneumonia; Active infections that have received systemic anti infective therapy within 2 weeks prior to the first administration (excluding antiviral therapy for hepatitis B or C)\n11. Current active hepatitis B subjects (HBsAg positive and HBV-DNA exceeding 1000 copies\u002Fml (200IU\u002Fml) or above the detection limit)\n12. Tumor invasion or compression of important surrounding organs (such as aorta, heart and pericardium, superior vena cava, trachea, esophagus, etc.) or the risk of developing esophagotracheal fistula or esophageal pleural fistula; Tumor mediastinal lymph node metastasis invading the trachea and main bronchus with the risk of bronchial fistula\n13. History of myocarditis, cardiomyopathy, and malignant arrhythmia in the past\n14. Within 6 months prior to the first administration, there is a history of esophageal and gastric varices, severe ulcers, unhealed wounds, gastrointestinal perforation, abdominal fistula, gastrointestinal obstruction, intra-abdominal abscess, or acute gastrointestinal bleeding\n15. Any arterial thromboembolic event, NCI CTCAE 5.0 grade 3 or higher venous thromboembolic event, transient ischemic attack, cerebrovascular accident, hypertensive crisis, or hypertensive encephalopathy occurred within 6 months prior to the first administration; Currently, there is hypertension and after treatment with oral antihypertensive drugs, the systolic blood pressure is ≥ 160mmHg or the diastolic blood pressure is ≥ 100mmHg\n16. History of severe bleeding tendency or coagulation dysfunction\n17. Received a live vaccine within 30 days prior to the first administration, or planned to receive a live vaccine during the study period\n18. Known to be allergic to any component of any anti-tumor drug; Known history of severe hypersensitivity reactions to other monoclonal antibodies\n19. Known history of mental illness, drug abuse, alcoholism, or drug use\n20. Pregnant or lactating women\n21. Any past or current diseases, treatments, or laboratory abnormalities that may confuse the research results, affect the participants' full participation in the study, or may not be in the best interests of the participants\n22. Local or systemic diseases caused by non malignant tumors, or diseases or symptoms secondary to tumors, which can lead to higher medical risks and\u002For uncertainty in survival evaluation, such as tumor like leukemia reactions (white blood cell count\\>20 × 109\u002FL), cachexia manifestations (such as known weight loss of more than 10% in the first 3 months of screening), etc","ALL","75 Years",{"count":54,"type":22},35,"INTERVENTIONAL",[57],"PHASE2","To evaluate the Efficacy and Safety of the Combination of Sintilimab With Platinum-doublet Chemotherapy and Adaptive Radiotherapy Strategy in the Treatment of Stage III Non-small Cell Lung Cancer Patients",[60,61,27],"NSCLC","Sintilimab",[63,64,27,65],"V20","stage III NSCLC","sintilimab","2026-03-20",{"date":68,"type":35},"2026-03-25",{"date":70,"type":35},"2025-08-29",{"date":72,"type":22},"2030-09",{"name":74,"class":42},"The Third Xiangya Hospital of Central South University",{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":81,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":83,"targetDuration":4,"studyType":55,"phases":85,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":43},"100453325","mr-linac-guided-ultra-hypofractionated-rt-for-prostate-cancer-smart-p01-and-smart-p02-100453325","NCT05183074","MR-linac Guided Ultra-hypofractionated RT for Prostate Cancer (SMART-P01 and SMART-P02)","Phase II Prospective Trial of MR-linac Based Stereotactic Ablative Radiotherapy for Patients With Localized (SAMRT-P01) and Oligo-metastatic (SMART-P02) Prostate Cancer","SMART-P01\u002F02","Inclusion Criteria:\n\n* Age≥18 years。\n* Histology confirmed prostate cancer.\n* Risk stratification, localised disease including patients with low-risk(cT1-T2a，PSA \\\u003C10ng\u002FmL，Gleason score≤6) who refuse active surveillance, favorable or unfavorable intermediate-risk and selected high-risk(cT2b-T3a or minimally T3b，PSA 10-40ng\u002FmL，Gleason score 7-8) disease.\n* Oligo-metastatic disease including patients with prostate in-situ and oligometastatic disease (no limit to mets number and organs, with all metastatic foci can be safely treated by radical SBRT dose)\n* ECOG 0-2\n* Postate gland volume ≤100cc\n* IPSS score of \\\u003C18\n* Informed consent: All patients must sign a document of informed consent indicating their understanding of the investigational nature and risks of the study before any protocol related studies are performed\n\nExclusion Criteria:\n\n* Contraindications to MRI.\n* TURP within the past 6 months\n* Ulcerative colitis, Crohn's Disease, ataxia telangiectasia, or systemic lupus erythematosus\n* Previous pelvic irradiation\n* Refuse contraception",{"count":84,"type":22},50,[86],"NA","1. To investigate the tolerability of MR-linac based stereotactic ablative radiotherapy (MRL-SBRT)for patients with localized prostate cancer\n2. To assess the acute and late toxicities, efficacy and quality of life for patients treated by MRL-SBRT\n3. To simulate the dose planning and assess the feasibility of simultaneous-boost for MR-prominent foci\n4. To investigate the relationship between the changes of blood and tissue biomarkers and manifestations on mp-MRI pre-\u002Fpost-MRL-SBRT, to further ascertain the predictive factors of local persisting and\u002For relapse disease",[26,89,90,91,27,92,93],"Radiotherapy Side Effect","Magnetic Resonance-linac","Stereotactic Ablative RT","Localised Disease","Oligometastatic Disease","2025-12-04",{"date":96,"type":35},"2025-12-11",{"date":98,"type":35},"2021-02-01",{"date":100,"type":22},"2027-12-31",{"name":102,"class":42},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":104,"slug":105,"hasResults":11,"nctId":106,"briefTitle":107,"officialTitle":107,"acronym":108,"eligibilityCriteria":109,"healthyVolunteers":11,"sex":51,"minAge":4,"maxAge":4,"enrollmentInfo":110,"targetDuration":4,"studyType":55,"phases":112,"briefSummary":113,"conditions":114,"keywords":116,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":43},"100612889","efficiency-of-contemporary-off-line-adaptive-radiotherapy-for-lung-cancer-100612889","NCT07259447","Efficiency of Contemporary Off-line Adaptive Radiotherapy for Lung Cancer","ECLAIR","Inclusion Criteria:\n\n1. Voluntary written informed consent of the participant or their legally authorized representative has been obtained prior to any screening procedures\n2. Patients diagnosed with non-small-cell lung cancer\n3. Locally advanced disease (≥Stage III)\n4. Treated with sequential or concurrent chemoradiotherapy\n\nExclusion Criteria:\n\n1. Small-cell lung cancer\n2. Non-small-cell lung cancer of early stage\n3. Mesothelioma",{"count":111,"type":22},30,[86],"Locally advanced non-small cell lung cancer (LA-NSCLC) patients could benefit in overall and progression-free survival from regular dosimetric treatment plan adaptations during radiotherapy. This is known as adaptive radiotherapy (ART). However, implementing an adaptive radiotherapy workflow presents a highly cumbersome process. First, repeated planning-CT imaging during treatment is required, which results in additional radiation dose for patients. Second, an ART workflow includes the repetition of various manual and semi-automated tasks such as target and organ-at-risk contouring on the images and dosimetric treatment planning. These obstacles hinder widespread ART implementation.\n\nTo avoid repeated planning-CT imaging, position-verification imaging can be utilized. Modern cone-beam CT (CBCT) imaging, integrated into the treatment unit, assists radiation therapists (RTTs) in administering the dose. Recent improvements in CBCT imaging sources and detectors have enhanced image quality. Moreover, it may be possible to calculate radiation dose directly on these CBCTs. Utilizing CBCT imaging for plan adaptation could also eliminate the need for an additional CT procedure, thereby increasing patient comfort.\n\nTo address the labor-intensive contouring and treatment planning steps, CE-marked and validated commercial AI applications are already being used to support organ contouring and accelerate the treatment-planning process. These tools are currently applied to pre-treatment planning CTs. The time efficiency of these contemporary tools in a prospective ART workflow has yet to be studied, as has the feasibility of applying these applications within a CBCT-based ART workflow.",[115,27],"NSCLC (Advanced Non-small Cell Lung Cancer)",[117],"CBCT-based Adaptive Radiotherapy","2025-11-20",{"date":120,"type":35},"2025-12-02",{"date":122,"type":35},"2024-06-21",{"date":124,"type":22},"2026-12-31",{"name":126,"class":42},"Universitaire Ziekenhuizen KU Leuven",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":134,"targetDuration":4,"studyType":55,"phases":136,"briefSummary":137,"conditions":138,"keywords":143,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":43},"100557749","phase-2-elimination-of-ptv-margins-based-on-online-adaptive-stereotactic-radiotherapy-for-early-stage-non-small-cell-lung-cancer-or-pulmonary-oligometastases-100557749","NCT06542159","Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases","Elimination of PTV Margins Based on Online Adaptive Stereotactic Radiotherapy for Early-stage Non-small Cell Lung Cancer or Pulmonary Oligometastases: a Prospective, Randomized, Controlled Phase II Study","Inclusion Criteria:\n\n* Histologically or PET-CT confirmed untreated early-stage non-small cell lung cancer (T1-2N0M0) that is inoperable or where the patient is unwilling to undergo surgery, or PET-CT\u002Fchest CT confirmed lung oligometastases (number of metastases ≤3, single lesion diameter ≤5cm).\n* Age 18 years or older, regardless of gender.\n* ECOG performance status score of 0-2.\n* Serum hemoglobin ≥ 80 g\u002FL, platelets ≥ 100,000\u002FμL, absolute neutrophil count ≥ 1,500\u002FμL.\n* Serum creatinine ≤ 1.25 times the upper normal limit (UNL) or creatinine clearance ≥ 60 ml\u002Fmin.\n* Serum bilirubin ≤ 1.5 times UNL, AST (SGOT) and ALT (SGPT) ≤ 2.5 times UNL, alkaline phosphatase ≤ 5 times UNL.\n* FEV1 ≥ 0.5 L.\n* Normal CB6 range.\n* The patient and their family agree and sign the informed consent form.\n\nExclusion Criteria:\n\n* Tumors with bronchial invasion are excluded.\n* Any other disease or condition that contraindicates radiotherapy (e.g., active infections, within 6 months post-myocardial infarction, symptomatic heart disease including unstable angina, congestive heart failure, or uncontrolled arrhythmias).\n* Pregnant or breastfeeding women, women who have not undergone pregnancy testing, and pregnant individuals.\n* Individuals with substance abuse issues, chronic alcoholism, or AIDS.\n* Individuals with uncontrollable seizures or loss of self-control due to psychiatric disorders.\n* Individuals with a history of severe allergies or specific sensitivities.",{"count":135,"type":22},130,[57],"This study aims to explore the safety and efficacy of eliminating the PTV (planning target volume) margins based on online adaptive stereotactic radiotherapy for patients with early-stage non-small cell lung cancer (NSCLC) or pulmonary oligometastases.",[27,139,140,141,142],"Stereotactic Body Radiotherapy","Non-small Cell Lung Cancer","Lung Oligometastases","Toxicity",[144,145,140,146,142],"Online adaptive radiotherapy","Stereotactic body radiotherapy","Lung oligometastases","2025-11-13",{"date":149,"type":35},"2025-11-17",{"date":151,"type":35},"2024-05-22",{"date":153,"type":22},"2028-04-21",{"name":155,"class":42},"Sun Yat-sen University",{"id":157,"slug":158,"hasResults":11,"nctId":159,"briefTitle":160,"officialTitle":160,"acronym":161,"eligibilityCriteria":162,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":163,"enrollmentInfo":164,"targetDuration":4,"studyType":55,"phases":166,"briefSummary":167,"conditions":168,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":173,"lastUpdatePostDateStruct":174,"startDateStruct":176,"completionDateStruct":178,"leadSponsor":180,"locationsCount":4},"100553930","phase-2-glioma-adaptive-radiotherapy-with-development-of-an-artificial-intelligence-workflow-100553930","NCT06492486","Glioma Adaptive Radiotherapy With Development of an Artificial Intelligence Workflow","GLADIATOR","Inclusion Criteria:\n\n* Histological diagnosis of diffuse glioma. Patients with IDH-negative GBM (stratum A) and IDH-mutant glioma (astrocytoma or oligodendroglioma) need radiotherapy (stratum B).\n\nAge: 18-70 years. Karnofsky Performance Scale (KPS) ≥60\n\nExclusion Criteria:\n\n* Multifocal or multicentric disease Not eligible for radical intent radiation. IDH status is unknown or uninterpretable (IHC or gene sequencing). Use of prior radiotherapy to the head-neck region or brain or chemotherapy. Contraindication\u002Funable to undergo MRI or PET scan during radiation.","70 Years",{"count":165,"type":22},60,[57],"Gliomas are common primary brain tumors in adults. Gliomas can be classified into different types based on tumor grade, histopathological features, and molecular characteristics. The common types of diffuse gliomas include glioblastoma, astrocytoma, and oligodendroglioma. The standard treatment for diffuse gliomas includes surgery followed by radiation and chemotherapy. As per standard institutional practice, a uniform dose of radiation is delivered to the disease area and MRI is done before and after the treatment. In this study, MRI and PET scan will be done before starting the treatment and standard dose of radiation will be delivered. The interval imaging will be done twice during the course of treatment with MRI and PET, followed by dose modifications. The CT, MRI, and PET will be combined. Based on PET imaging, specific dose will be altered and delivered to specific areas. Dose modification will be done with the help of artificial intelligence. Participant's assessment will be done at regular intervals.\n\nModifications in radiation plans are done based on the changes in disease seen in scans is likely to improve the accuracy of RT treatments. Dose modifications based on imaging to resistant areas will help achieve better tumor control, reduce treatment-related toxicities, precise delivery of the RT and adjusting doses to the organs at risk (OAR) and changes in disease leading to better treatment compliance. Creating an artificial intelligence framework in radiation oncology promises to improve quality of workflow, treatment planning and RT delivery.\n\nThe aim of the study is to develop an artificial intelligence workflow for treatment of glioma with adaptive radiotherapy. This study will be conducted in Tata Memorial Centre on a population of 60 patients for a duration of 2 years. The total study duration is 4 years.",[169,170,27,171],"Diffuse Glioma","Glioblastoma","Artificial Intelligence","NOT_YET_RECRUITING","2025-09-15",{"date":175,"type":35},"2025-09-16",{"date":177,"type":22},"2025-11-30",{"date":179,"type":22},"2028-07-30",{"name":181,"class":42},"Tata Memorial Centre",{"id":183,"slug":184,"hasResults":11,"nctId":185,"briefTitle":186,"officialTitle":187,"acronym":4,"eligibilityCriteria":188,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":52,"enrollmentInfo":189,"targetDuration":4,"studyType":55,"phases":191,"briefSummary":192,"conditions":193,"keywords":4,"overallStatus":172,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":4},"100599124","the-efficacy-of-mr-guided-online-adaptive-radiotherapy-for-locally-advanced-rectal-cancer-100599124","NCT07080411","the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal Cancer","A Prospective Study on the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal Cancer","Inclusion Criteria:\n\n1. Age 18-75 years, regardless of gender;\n2. Staged as II\u002FIII (cT3-T4N0 or cT2-4N+, no distant metastasis) by MRI or endoscopic ultrasound (according to the AJCC Cancer Staging Manual, 8th Edition);\n3. Fibrocolonoscopy or digital rectal examination confirms the lower border of the lesion is ≤10 cm from the anal verge;\n4. Pathologically confirmed or reviewed diagnosis of rectal adenocarcinoma;\n5. ECOG performance status of 0-1;\n6. Laboratory test results meeting the following criteria: Hemoglobin ≥ 90 g\u002FL, white blood cells ≥ 3.5×10⁹\u002FL; Neutrophils ≥ 1.5×10⁹\u002FL, platelets ≥ 100×10⁹\u002FL; Creatinine ≤ 1.0× upper normal limit (UNL), blood urea nitrogen (BUN) ≤ 1.0× UNL; Alanine aminotransferase (ALT) ≤ 1.5× UNL; Aspartate aminotransferase (AST) ≤ 1.5× UNL; Alkaline phosphatase (ALP) ≤ 1.5× UNL; Total bilirubin (TBIL) ≤ 1.5× UNL; Urine protein (-); normal bleeding and clotting time.\n7. No history of allergy to 5-Fu drugs or platinum-based drugs;\n8. Primary rectal cancer patients must not have undergone surgery (except palliative colostomy), chemotherapy, or other antitumor treatments from diagnosis to enrollment;\n9. No prior radiation therapy to the intended treatment site;\n10. Signed informed consent form.\n\nExclusion Criteria:\n\n1. Presence of MRI-incompatible metal implants or claustrophobia;\n2. Previous treatment with anti-PD-1\u002FL1, anti-CTLA-4 immunotherapy, or other experimental immunotherapeutic drugs;\n3. History of severe autoimmune diseases, including active inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), rheumatoid arthritis, scleroderma, systemic lupus erythematosus, autoimmune vasculitis (e.g., Wegener's granulomatosis), etc.;\n4. Symptomatic interstitial lung disease or active infectious\u002Fnon-infectious pneumonia;\n5. Risk factors for intestinal perforation, such as active diverticulitis, intra-abdominal abscess, gastrointestinal (GI) obstruction, abdominal malignancies, or other known predisposing conditions;\n6. History of other malignancies, except for curable non-melanoma skin cancer or cervical carcinoma in situ;\n7. Active infections, heart failure, myocardial infarction within the past 6 months, unstable angina, or unstable arrhythmia;\n8. Physical examination or clinical findings that, in the investigator's judgment, may interfere with results or increase the patient's risk of treatment complications, or other uncontrolled medical conditions;\n9. Women who are pregnant or breastfeeding;\n10. Congenital or acquired immunodeficiency disorders, including human immunodeficiency virus (HIV) infection, or history of organ transplantation or allogeneic stem cell transplantation.\n11. Active hepatitis B virus (HBV) infection (HBV-DNA ≥2000 U\u002FmL), hepatitis C virus (HCV) infection, or active tuberculosis infection;\n12. Prior administration of a cancer vaccine or receipt of any other vaccine within 4 weeks before treatment initiation.\n\n    (Note: Inactivated vaccines, such as seasonal flu shots, are permitted, whereas live attenuated vaccines, such as intranasal formulations, are prohibited.)\n13. Concurrent use of other immunomodulators, chemotherapy, investigational drugs, or long-term corticosteroid therapy will exclude the patient from enrollment.\n14. Patients with psychiatric disorders, substance abuse, or social issues that may compromise compliance, as assessed by the investigator, will be excluded.\n15. Patients with a known allergy or contraindication to the study treatment.",{"count":190,"type":22},49,[86],"Based on preliminary findings on the motion error of the clinical target volume (CTV) in MR-guided adaptive radiotherapy (MRgART) for locally advanced rectal cancer (LARC), this study aims to reduce CTV-to-PTV margins and evaluate the complete response (CR) rate following MRgART in LARC patients. Additionally, it will investigate the safety and tolerability of MRgART, as well as its impact on:\n\n3-year organ preservation rate\n\nLocal recurrence rate in patients under a \"watch-and-wait\" approach\n\n3-year overall survival (OS), disease-free survival (DFS), and local progression-free survival (LPFS).\n\nFurthermore, by analyzing ADC maps of the gross tumor volume (GTV), this study will characterize treatment responses and spatial deformation in metabolically active tumor subregions. These insights may inform future dose-escalation strategies for LARC radiotherapy, with the ultimate goal of improving prognosis and quality of life in this patient population.",[194,27],"Rectal Cancer","2025-07-14",{"date":197,"type":35},"2025-07-23",{"date":199,"type":22},"2025-08-01",{"date":201,"type":22},"2029-12-31",{"name":102,"class":42},{"id":204,"slug":205,"hasResults":11,"nctId":206,"briefTitle":207,"officialTitle":208,"acronym":4,"eligibilityCriteria":209,"healthyVolunteers":11,"sex":210,"minAge":18,"maxAge":52,"enrollmentInfo":211,"targetDuration":4,"studyType":55,"phases":213,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":221,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":43},"100565396","phase-3-moderated-hypofractionated-online-adaptive-radiotherapy-in-cervical-cancer-100565396","NCT06641635","Moderated Hypofractionated Online Adaptive Radiotherapy in Cervical Cancer","A Multicenter, Non-inferiority, Phase 3, Randomized Controlled Study of Moderated Hypofractionated Online Adaptive Radiotherapy for Cervical Cancer","Inclusion Criteria:\n\n1. The patient is fully voluntary and has the capacity for autonomy, signing the informed consent form 30 days prior to enrollment\n2. Age ≥18 and ≤75 years\n3. FIGO stage IB-IIIB cervical cancer; IIIC1 (lymph node metastasis ≤2 cm, without common iliac lymph node metastasis)\n4. Pathologically diagnosed as squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma\n5. Concurrent weekly cisplatin therapy ± immunotherapy\n6. Able to undergo brachytherapy\n7. ECOG performance status of 0-1, with an expected ability to tolerate lying flat for half an hour.\n\nExclusion Criteria:\n\n1. Patients who have undergone cervical cancer surgery, excluding pelvic lymphadenectomy or pelvic lymph node dissection, or cervical conization\n2. FIGO stages IA, IIIC2, IVA, or IVB\n3. FIGO stage IIIC1 with lymph nodes \\>2 cm, or with common iliac lymph node metastasis\n4. History of prior abdominal or pelvic radiotherapy\n5. Pregnant or breastfeeding women\n6. Patients with active infections or fever\n7. Other severe diseases that may significantly affect clinical trial compliance, such as unstable heart disease, kidney disease, chronic hepatitis requiring treatment, poorly controlled diabetes, or mental disorders.","FEMALE",{"count":212,"type":22},440,[214],"PHASE3","The most common external beam radiotherapy fractionation scheme for cervical cancer is 45-50.4 Gy delivered in 25-28 fractions. However, prolonged treatment duration can lead to insufficient availability of medical resources. We hope to assess the safety and efficacy of moderated hypofractionated online adaptive radiotherapy in combination with brachytherapy in patients with cervical cancer in a multicenter study.",[217,27],"Cervical Cancer",[217,219,27,220],"Moderated Hypofractionated Radiotherapy","Randomized controlled trial","2025-03-13",{"date":223,"type":35},"2025-03-18",{"date":225,"type":35},"2024-11-19",{"date":227,"type":22},"2029-10-31",{"name":229,"class":42},"Peking Union Medical College Hospital",{"id":231,"slug":232,"hasResults":11,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":236,"eligibilityCriteria":237,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":55,"phases":239,"briefSummary":240,"conditions":241,"keywords":245,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":247,"startDateStruct":249,"completionDateStruct":251,"leadSponsor":253,"locationsCount":43},"100532697","adaptive-radiotherapy-in-head-and-neck-tumor-patients-100532697","NCT06216171","Adaptive Radiotherapy in Head and Neck Tumor Patients","Prospective Randomized Study on Adaptive Radiotherapy in Head and Neck Tumor Patients (Pro- Head and Neck -ART, ProHEART)","ProHEART","Inclusion Criteria:\n\nECOG 0\u002F1 No prior cancer treatment\n\nExclusion Criteria:\n\nECOG 2-4 Prior cancer treatment",{"count":111,"type":22},[86],"Most newly diagnosed oropharyngeal and hypopharyngeal cancers are treated with radiochemotherapy with curative intent. If the field-set UP margins are broad, the consequence may be that quality of life is impaired. The study group of Nutting et al. (2023) investigated this year whether dysphagia-optimized intensity-modulated radiotherapy can reduce the radiation dose to structures associated with dysphagia and aspiration and improve swallowing function compared to standard IMRT (Nutting C, Finneran L, Roe J, Petkar I, Rooney K, Hall E; DARS Triallist Group. Dysphagia-optimized intensity-modulated radiotherapy versus standard radiotherapy in patients with pharyngeal cancer - Authors' reply. Lancet Oncol. 2023 Oct;24(10):e398. doi: 10.1016\u002FS1470-2045(23)00457-6. PMID: 37797636.) The study group concluded that the results suggest that dysphagia-optimized IMRT improves patient-reported swallowing function compared to standard IMRT. DO-IMRT should be considered the new standard of care for patients receiving radiotherapy for pharyngeal cancer, and ART could further improve outcomes.",[242,243,27,244],"Head and Neck Neoplasms","Head and Neck Cancer","Optimization",[242,243,27,244],"2024-09-25",{"date":248,"type":35},"2024-09-27",{"date":250,"type":35},"2024-01-25",{"date":252,"type":22},"2028-01-30",{"name":254,"class":42},"University Hospital, Essen",{"id":256,"slug":257,"hasResults":11,"nctId":258,"briefTitle":259,"officialTitle":260,"acronym":261,"eligibilityCriteria":262,"healthyVolunteers":11,"sex":51,"minAge":18,"maxAge":4,"enrollmentInfo":263,"targetDuration":4,"studyType":55,"phases":264,"briefSummary":265,"conditions":266,"keywords":271,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":246,"lastUpdatePostDateStruct":275,"startDateStruct":276,"completionDateStruct":278,"leadSponsor":280,"locationsCount":43},"100532577","prospective-validation-of-adaptive-radiotherapy-art-in-patients-with-head-and-neck-tumors-100532577","NCT06214611","Prospective Validation of Adaptive Radiotherapy (ART) in Patients With Head and Neck Tumors","Adaptive Radiotherapy in the Treatment of Patients With a Histologically Confirmed Malignant Tumor in the Head and Neck Region: Prospective Validation of ART in Patients With HNT (Prospektive Validierung Der ART Bei Patientinnen Und Patienen Mit Kopf-Hals Tumoren,)","ART in HNT","Inclusion Criteria:\n\n1. ECOG 0-1\n2. Histopathology confirmation\n3. Compliance\n4. Tumor in the head and neck region\n5. Indication for radiotherapy\n\nExclusion Criteria:\n\n1\\. Pregnancy",{"count":84,"type":22},[86],"Adaptive radiotherapy (ART) includes image-guided radiotherapy (IGRT) and also offers further possibilities for plan adaptation. A particularly high benefit can be expected for patients in whom the clinical target volume (CTV) can show a significant change in shape from fraction to fraction due to anatomical deviations. The shape and position constancy of the CTV during the course of the series is examined in this trial. Dosimetric disadvantages of this type have not been reported so far. The aim of this study is to identify patients who benefit from ART at an early stage and to select them for this method, and then to continue to offer ART to this patient group. If a relevant reduction in the minimum planning target volume (PTV) margins with ART compared to IGRT is demonstrated in this study, patients could be treated with ART.",[243,27,267,268,269,270],"Radiation","Optimized Treatment","Protection of Organs at Risk","Dysphagia Reduction",[243,27,272,273,274],"Protection of organs at risk","Optimized treatment","Dysphagia reduction",{"date":248,"type":35},{"date":277,"type":35},"2023-11-15",{"date":279,"type":22},"2027-12-15",{"name":254,"class":42},{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":287,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":210,"minAge":18,"maxAge":4,"enrollmentInfo":289,"targetDuration":4,"studyType":55,"phases":290,"briefSummary":291,"conditions":292,"keywords":298,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":307,"lastUpdatePostDateStruct":308,"startDateStruct":310,"completionDateStruct":312,"leadSponsor":314,"locationsCount":43},"100533802","adaptive-radiotherapy-in-patients-with-gynecological-tumors-100533802","NCT06230549","Adaptive Radiotherapy in Patients With Gynecological Tumors","Prospective Randomized Validation of Adaptive Radiotherapy in Patients With Gynecological Tumors and Indication for Radiotherapy","ProART","Inclusion Criteria:\n\nECOG 0-1 confirmation by histophatology MR of the pelvis staging\n\nExclusion Criteria:\n\nRecurrent disease Prior Radiotherapy in pelvic region stage pM1 or cM1",{"count":111,"type":22},[86],"Prospective randomized evaluation of adaptive radiotherapy in the definitive radiotherapy of locally advanced gynecologic carcinoma (e.g. cervical carcinoma, endometrial carcinoma, vaginal carcinoma), in the postoperative situation or first series of external beam radiotherapy and in patients in whom radical surgery or HDR brachytherapy as dose boost is not an option.",[293,27,267,294,244,295,296,297],"Gynecological Tumor","Curative Treatment","Adaptive Radiation Therapy","Image Guided Radiotherapy","Cervical Carcinoma",[299,300,301,302,303,304,305,306],"gynecological tumor","adaptive radiotherapy","radiation","curative treatment","optimization","adaptive radiation therapy","image guided radiotherapy","Cervical carcinoma","2024-02-07",{"date":309,"type":35},"2024-02-09",{"date":311,"type":35},"2024-01-15",{"date":313,"type":22},"2026-12-15",{"name":254,"class":42}]